Antioxidant Therapy For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Antioxidant therapy represents a fundamental approach to treating neurodegenerative diseases by counteracting oxidative stress, a key pathological mechanism in Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other disorders. This therapy aims to replenish endogenous antioxidant defenses, scavenge reactive oxygen species (ROS), and protect neurons from oxidative damage. [1]
'''Antioxidant Therapy for Neurodegenerative Diseases''' targets oxidative stress, a fundamental pathological mechanism in Alzheimer's disease, Parkinson's disease, ALS, Huntington's disease, and other disorders. This page covers the molecular basis of oxidative damage, antioxidant therapeutic strategies, clinical evidence, and challenges. [2]
{| class="infobox" [3]
|-
! colspan="2" style="background:#e8f4ea;font-size:120%;" | Antioxidant Therapy
|-
| '''Category''' || Therapeutic Intervention
|-
| '''Target Conditions''' || AD, PD, ALS, HD, Stroke, MSA
|-
| '''Mechanism''' || ROS scavenging, Nrf2 activation
|-
| '''Delivery Routes''' || Oral, IV, Intranasal
|-
| '''Clinical Stage''' || Approved (various), Clinical Trials
|-
| '''Key Agents''' || Vit E, CoQ10, MitoQ, Edaravone
|}
== Overview ==
Oxidative stress results from an imbalance between reactive oxygen species (ROS) production and cellular antioxidant defenses. The brain is particularly vulnerable due to high oxygen consumption, lipid content, and limited regenerative capacity. Oxidative damage contributes to protein misfolding, lipid peroxidation, DNA damage, and mitochondrial dysfunction in neurodegenerative diseases.
== Molecular Mechanisms ==
=== Sources of ROS in Neurodegeneration ===
=== Antioxidant Defense Systems ===
== Therapeutic Strategies ==
=== Direct Antioxidants ===
==== Vitamin E (α-Tocopherol) ===
==== Coenzyme Q10 (CoQ10) ===
==== MitoQ (Mitoquinone) ===
==== Edaravone (Radicava) ===
=== Nrf2 Activators ===
=== Metal Chelation ===
=== Mitochondrial-Targeted Antioxidants ===
== Disease-Specific Applications ==
=== Alzheimer's Disease ===
=== Parkinson's Disease ===
=== ALS ===
=== Huntington's Disease ===
=== Stroke ===
== Clinical Trial Evidence ==
{| class="wikitable"
|-
! Agent
! Condition
! Phase
! Outcome
! PMID
|-
| CoQ10 1200mg/d
| PD
| Phase III
| Negative (failed primary)
| 22288676 |
|---|
| CoQ10 3000mg/d |
| Early PD |
| Phase II |
| Positive (slowed decline) |
| 15919595 |
| - |
| Edaravone |
| ALS |
| Phase III |
| Approved (slowed decline) |
| 28124998 |
| - |
| Vitamin E |
| AD |
| Phase III |
| Mixed |
| 15056666 |
| - |
| MitoQ |
| PD |
| Phase II |
| Safe, inconclusive efficacy |
| 29331074 |
| } |
== Challenges and Limitations ==
== Future Directions ===
== See Also ==
== References ==
The study of Antioxidant Therapy For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Liu J, Wang L, Zheng L, et al. Antioxidant therapy for Alzheimer's disease. 2021. ↩︎
Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. 2015. ↩︎
Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. 2019. ↩︎